文献速递MDS 与骨髓增殖性肿瘤

MIPSS70-plus对中国原发性骨髓纤维化患者预后价值的评估

[Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

该研究回顾性分析113例中国PMF患者,评估MIPSS70-plus预后积分系统的价值。结果显示MIPSS70-plus各风险组2年总生存率差异显著(P<0.001),且其预测效能优于DIPSS(P=0.001)。

要点

  • MIPSS70-plus低危、中危、高危、极高危组2年OS分别为100%、89.7%、64.8%、35.0%。
  • MIPSS70-plus对生存的预测效能显著优于DIPSS(P=0.001)。
  • 中国PMF患者中JAK2V617F突变占55.8%,三阴性占22.1%。

核心结论

  • MIPSS70-plus较DIPSS对中国PMF患者有更好的预后评估效能。

研究设计与样本

  • 回顾性分析113例中国PMF患者,采用Kaplan-Meier法、Log-rank检验和Cox回归模型分析预后因素。
  • 采用似然比检验比较MIPSS70-plus与DIPSS的预测效能。

主要发现

  • 中位年龄55(20~70)岁,男71例,女42例。
  • MIPSS70-plus低危、中危、高危、极高危组分别28例(26.7%)、20例(19.0%)、41例(39.0%)、16例(15.3%)。
  • 2年OS分别为100%、89.7%(95%CI 76.2%~100.0%)、64.8%(95%CI 47.0%~82.6%)、35.0%(95%CI 10.3%~59.7%),P<0.001。
  • MIPSS70-plus的-2log似然比为86.355,显著低于DIPSS的95.990(P=0.001)。

关键数值与推荐

  • 染色体核型预后良好组90例(79.6%),预后不良组23例(20.4%)。
  • JAK2V617F突变63例(55.8%),CALR外显子9突变20例(17.7%),MPLW515突变5例(4.4%),三阴性25例(22.1%)。
  • 高分子风险突变:ASXL1 44例(38.9%)、SRSF2 8例(7.1%)、IDH1/2 5例(4.4%)、EZH2 4例(3.5%);至少一种HMR突变51例(45.1%)。

临床怎么用

  • 对中国PMF患者可采用MIPSS70-plus进行预后分层,其预测效能优于DIPSS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis (PMF) . Methods: A total of 113 Chinese patients with PMF were retrospectively analyzed. The Kaplan-Meier method, Log-rank test, and Cox proportional hazard regression model were performed to evaluate the prognostic factors. The likelihood ratio test was used to evaluate the predictive power between MIPSS70-plus and DIPSS systems. Results: The median age of the Chinese patients was 55 (range: 20-70) years, including 71 males and 42 females. According to the standard of MIPSS70-plus system, 99 patients (79.6% ) had a favorable karyotype and 23 patients (20.4% ) had an unfavorable karyotype. JAK2V617F in 55.8% (n=63) , CALR exon9 in 17.7% (including 15 CALR type 1 and 5 CALR type 2, n=20) , MPLW515 in 4.4% (n=5) , and triple negative (no detectable JAK2, MPL, and CALR mutations) in 22.1% of patients in our cohort were found by target-specific next-generation sequencing approach. At least one high-molecular risk mutations were presented in 45.1% (n=51) of patients, with ASXL1 in 38.9% (n=44) , SRSF2 in 7.1% (n=8) , IDH1/2 in 4.4% (n=5) , and EZH2 in 3.5% (n=4) of patients. A total of 28 patients (26.7% ) were in low risk, 20 (19.0% ) in intermediate risk, 41 (39.0% ) in high risk, and 16 (15.3% ) in very-high risk categories, which were delineated for the MIPSS70-plus model. A 2-year OS was 100% in low risk, 89.7% (95% CI 76.2% -100.0% ) in intermediate risk, 64.8% (95% CI 47.0% -82.6% ) in high risk, and 35.0% (95% CI 10.3% -59.7% ) in very-high risk categories, which had a significant difference (P<0.001) . A significantly higher predictive power for survival of the MIPSS70-plus group was observed compared with the DIPSS group (P=0.001, -2 log-likelihood ratios of 86.355 vs 95.990 for the MIPSS70-plus and DIPSS systems, respectively) . Conclusion: The MIPSS70-plus had significantly higher predictive power than the DIPSS. 目的: 评价MIPSS70-plus预后积分系统对中国原发性骨髓纤维化(PMF)患者的预后评估价值。 方法: 回顾性分析113例PMF患者的临床资料,应用Log-rank和COX回归模型进行预后相关因素分析;应用似然比检验比较MIPSS70-plus和动态国际预后积分系统(DIPSS)的预后评估效能。 结果: 113例PMF患者中男71例,女42例,中位年龄55(20~70)岁。依据MIPSS70-plus染色体核型分组标准,染色体核型预后良好组90例(79.6%),预后不良组23例(20.4%)。二代测序基因突变检测结果示,JAK2V617F突变63例(55.8%),CALR外显子9突变20例(17.7%)(其中1型CALR突变15例,2型CALR突变5例),MPLW515突变5例(4.4%),25例(22.1%)未检测到JAK2、MPL和CALR基因突变(三阴性)。高分子风险(HMR)突变检出率依次为ASXL1突变44例(38.9%)、SRSF2突变8例(7.1%)、IDH1/2突变5例(4.4%)、EZH2突变4例(3.5%);51例患者(45.1%)有1种以上高危基因突变。MIPSS70-plus预后积分低危组、中危组、高危组、极高危组分别为28例(26.7%)、20例(19.0%)、41例(39.0%)、16例(15.3%),2年预期总生存率分别为100%、89.7%(95%CI 76.2%~100.0%)、64.8%(95%CI 47.0%~82.6%)、35.0%(95%CI 10.3%~59.7%)(P<0.001)。MIPSS70-plus的-2log似然比显著低于DIPSS(86.355对95.990,P=0.001),表明MIPSS70-plus较DIPSS有更准确的预后分组预测效能。 结论: MIPSS-70plus较DIPSS预后积分系统对中国PMF患者有更好的预后评估效能。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yan X, Li B, Qin TJ, et al. [Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33677863. doi:10.3760/cma.j.issn.0253-2727.2021.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。